AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00075218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
Trial: NCT00075218
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
Trial: NCT05840640
Drug: Standard Medical Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy involves primary treatment with normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
Trial: NCT01627873
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
Trial: NCT01627873
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
Trial: NCT01388595
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4. Placebo inhaler to SM, FP, SM+FP Manufacturer: Cipla Ltd Active ingredients: None Propellants: HFA 134a Imported \& QP release tested in UK : DHP Clinical supplies, Powys, UK
Trial: NCT01620554
Drug: BF2.649
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule per week during 2 weeks
Trial: NCT01620554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule per week during 2 weeks
Trial: NCT05170841
Drug: Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as one single tablet to be taken every 8 hours
Trial: NCT05170841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as one tablet if matching Dexketoprofen Trometamol 25 mg and Tramadol Hydrochloride 75 mg or two capsules if matching Tramadol Hydrochloride 100 mg
Trial: NCT01784757
Drug: ODM-201 capsule formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule formulation of ODM-201
Trial: NCT02760797
Drug: RO7009789
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7009789 will be administered IV every 3 weeks (every cycle).
Trial: NCT01386346
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 625 mg/m2 orally twice daily beginning on Day 3 or 5 and will be taken without interruption for each 21-day cycle.
Trial: NCT02219633
Drug: LEO 39652 cream
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied for 21 days
Trial: NCT03970096
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03970096
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03806790
Drug: LEO 90100 foam
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.
Trial: NCT02352337
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfusion :oxaliplatine, Irinotecan ,folinic acid, 5FU bolus and continue
Trial: NCT02352337
Drug: LV5FU2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfusion: Folinic Acid,5FU Bolus,5FU continue
Trial: NCT02352337
Drug: FOLFIRI.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfusion :Irinotecan,Acide folinique ,5FU continue
Trial: NCT01908127
Drug: injection of local anesthesia solution
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A topical anesthesia and injection of local anesthesia solution using mandibular alveolar nerve block technique was performed by the dentist
Trial: NCT03806790
Drug: Dovobet® ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.
Trial: NCT01140074
Drug: Zinc Sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc Sulfate in sugar sirup will be given orally in dosis of 10-20 mg per day for 10 days
Trial: NCT00100165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by mouth twice a day for 4 weeks
Trial: NCT00409435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one capsule per day for 3 days
Trial: NCT03376594
Drug: Benjakul Extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 patients taking Benjakul Extract dosage 100 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
Trial: NCT00427492
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02204371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib matching placebo is available as tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
Trial: NCT03643744
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14 Celecoxib 200mg taken 1 in the morning and 1 in the evening.
Trial: NCT03643744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 placebo capsules taken 1 in the morning and 1 in the evening.
Trial: NCT01720056
Drug: Kenalog 10
RxNorm normalized name: Kenalog 10 MG/ML Injectable Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02866175
Drug: Vitamin K antagonist
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VKA once-daily dosing for target international normalized ratio between 2.0 and 3.0, inclusive
Trial: NCT03758365
Drug: MC2-01 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Trial: NCT03758365
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Trial: NCT03943251
Drug: HEC113995PA•H2O tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5-、5-、10-、20-、40-、60-、80mg HEC113995PA•H2O tablet in day1.
Trial: NCT03943251
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5-、5-、10-、20-、40-、60-、80mg Placebo tablet in day1.
Trial: NCT04669665
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal placebo
Trial: NCT00843531
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day PO (oral)
Trial: NCT02182102
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00992069
Drug: TMC207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 400 mg in the morning
Trial: NCT02737306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in parenteral solution.
Trial: NCT01474278
Drug: RO5028442
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT00901407
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo: 1-2 tablets bid; 10 weeks
Trial: NCT02736760
Drug: Daylight photodynamic therapy using Methylaminolevulinate (MAL)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the Daylight photodynamic therapy arm the patients will apply a sunscreen to the whole face which is followed by lesion preparation of AKs. Following this, MAL will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours.~5 photodynamic therapy treatment sessions (visits 1-5) will be performed within 18 months.
Trial: NCT00007878
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00007878
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01497483
Drug: Pravastatin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg with placebo.
Trial: NCT03372317
Drug: 18F-MK-6240
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Results of the 18F-MK-6240 PET scan will be correlated with other observations.
Trial: NCT02315898
Drug: Treatment-inhaled tPA
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients with acute plastic bronchitis (fibrin airway casts) will receive inhaled tPA treatment. The tPA regimen will consist of 5mg every six hours for a total of 72 hours.
Trial: NCT04043845
Drug: LY3214996
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
Trial: NCT00343980
Drug: inhaled human insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target dose titration scheme, pre-prandial, inhalation.
Trial: NCT04355468
Drug: Opioid Anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperatively, fentanyl in fractional doses of 1-3 µg∙kg-1 were applied if the heart rate (HR; Heart Rate) or mean blood pressure (MBP; Mean Blood Pressure) increased by more than 20% above the baseline value obtained just before surgery commencement.
Trial: NCT03719586
Drug: MAb114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg of body weight administered intravenously on Day 1 as a single infusion
Trial: NCT01784042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01948505
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01948505
Drug: Placebo for IV acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02476526
Drug: Acetylcysteine Inhalation
RxNorm normalized name: acetylcysteine Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)
Trial: NCT02328300
Drug: FLT PET/MR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will be injected with FLT, a common PET radiotracer for brain tumors and lesions, and then will complete one (1) PET/MR scan.
Trial: NCT03120234
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03120234
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: o.9% normal saline will be used instead of ketamine
Trial: NCT03915938
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered in an identical way than ketamine.
Trial: NCT01904058
Drug: LUM001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01904058
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03079921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mL bag of Normal Saline Solution (NSS).
Trial: NCT02717611
Drug: ACP-196 (acalabrutinib)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACP-196 100 mg to be administered orally (PO) twice a day BID.
Trial: NCT03065309
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bolus dose
Trial: NCT03964090
Drug: TEDD-R
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide, etoposide, doxil, dexamthasone, and rituximab (TEDD-R) given every 21 days for cycles 1-4
Trial: NCT03964090
Drug: TEDDI-R
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide, etoposide, doxil, dexamthasone, ibrutinib and rituximab (TEDDI-R) given every 21 days for cycles 1-4
Trial: NCT03964090
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate on days 1 and day 5 of cycles 2-5 (all arms), as applicable
Trial: NCT03980483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.
Trial: NCT03980483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cap (containing lactose) to be administered orally.
Trial: NCT02001558
Drug: Microcyn
RxNorm normalized name: MICROCYN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily for the earlier of total wound closure or Week 24
Trial: NCT00985478
Drug: SLV342
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg once daily - Maximal Tolerated Dose
Trial: NCT00985478
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01479127
Drug: ABT-SLV187
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01479127
Drug: Oral Levodopa/Carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; contains 100 mg levodopa and 10 mg carbidopa
Trial: NCT00531973
Drug: liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)
Trial: NCT02427880
Drug: Acetazolamide and Hydrochlorothiazide Followed by Furosemide
RxNorm normalized name: furosemide and potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02427880
Drug: Furosemide and Hydrochlorothiazide Followed by Furosemide
RxNorm normalized name: furosemide and potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03434197
Drug: Diclofenac diethylamine
RxNorm normalized name: diclofenac diethylamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
Trial: NCT04073498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered by SC injection according to cohort dosing instructions.
Trial: NCT04023552
Drug: TQJ230
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQJ230 80 mg injected monthly administered subcutaneously
Trial: NCT04023552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match TQJ230 prefilled syringe to be injected subcutaneously
Trial: NCT00413244
Drug: AndroGel 5 Grams
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
Trial: NCT00413244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
Trial: NCT03330288
Drug: Theraflex, BAY 874017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day
Trial: NCT02917733
Drug: LY3039478
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00140933
Drug: MK0966; rofecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00140933
Drug: Comparator: diclofenac, placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02653872
Drug: AZD7986
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, single dose, dilution from concentrate
Trial: NCT04125888
Drug: Allergy immunotherapy (AIT)
RxNorm normalized name: Callergy Clear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy for different types of allergies
Trial: NCT04633577
Drug: 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline
Trial: NCT02978326
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.
Trial: NCT00837356
Drug: Advate®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session
Trial: NCT04195997
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: heparin during left atrial appendage occlusion.
Trial: NCT01775761
Drug: Period 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
Trial: NCT00991198
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no O2
Trial: NCT00642538
Drug: MKC253 Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Powder, prandial
Trial: NCT00642538
Drug: Technosphere Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Powder, prandial
Trial: NCT00642538
Drug: subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10µg Exenatide, prandial
Trial: NCT04426708
Drug: HMS5552
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of HMS5552 25mg
Trial: NCT01272557
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m2 i.v. on day 1 every 21 days Sorafenib 400 mg bid (oral) from day 3-19 every 21 days. Maximum accumulative dose of doxorubicin: 360 mg/m2 (thereafter sorafenib monotherapy continuously until progression or unacceptable toxicity).
Trial: NCT04104646
Drug: CHF6563 matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual CHF6563 matched placebo administration
Trial: NCT03523234
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoposide with cisplatin/carboplatin
Trial: NCT00788957
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous infusion
Trial: NCT02809183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension
Trial: NCT02809183
Drug: TRC101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension
Trial: NCT02486796
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preparation of melatonin
Trial: NCT03387098
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Trial: NCT03387098
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate